PMID- 29687693
OWN - NLM
STAT- MEDLINE
DCOM- 20190506
LR  - 20190506
IS  - 0393-974X (Print)
IS  - 0393-974X (Linking)
VI  - 32
IP  - 4
DP  - 2018 Jul-Aug
TI  - Emerging from gastroesophageal reflux (EMERGE): an Italian survey - I the 
      viewpoint of the gastroenterologist.
PG  - 973-981
LID - 30 [pii]
AB  - Gastroesophageal reflux disease (GERD) is defined as a "disease that develops 
      when the reflux of stomach contents induces troublesome symptoms and/or 
      complications". From a therapeutic point of view, many options have been 
      proposed, including proton pump inhibitors (PPI), antihistamines (H2- receptor 
      antagonists), antacid chemical compounds, antireflux barrier (using alginates), 
      prokinetics, inhibitors of gastric sphincters, protection of mucosal tissue, 
      neuromodulators, nociceptor antagonists, lifestyle modification, and surgery. A 
      new medical compound has been recently launched in Italy: Marial(R) (manufactured 
      by Aurora, Milan, Italy) containing magnesium alginate and E-Gastryal(R). The aim 
      of this survey was to analyse the patients' characteristics and the prescriptive 
      approach considering both the past or current treatments and clinical features 
      during a visit in 56 gastroenterological centers, distributed in the whole of 
      Italy. One thousand eight hundred forty-nine patients (46.5% males, and 53.5% 
      females, mean age 48.59 years) were visited. Patients with positive reflux 
      symptoms index (RSI+) had higher GIS scores than RSI- subjects. PPIs (both as 
      monotherapy or plus add-on) were the most common medication prescribed before the 
      visit. There was a significant change of prescription to Marial(R) at the visit. 
      More precisely,, Marial(R) was preferentially prescribed to about a quarter of the 
      patients, particularly to those with lower GIS score, whereas PPI plus add-on 
      option was preferred for patients with higher GIS score. In conclusion, the 
      current experience demonstrated that GERD may be managed considering a 
      patient-centred work-up by using the GIS questionnaire. GIS score may be able to 
      define the medication choice that includes also the new medical compound Marial(R).
CI  - Copyright (c) by BIOLIFE, s.a.s. This publication and/or article is for individual 
      use only and may not be further reproduced without written permission from the 
      copyright holder. Unauthorized reproduction may result in financial and other 
      penalties
FAU - Bianchetti, M
AU  - Bianchetti M
AD  - Gastroenterologia - Humanitas Mater Domini, Castellanza (VA), Italy
FAU - Peralta, S
AU  - Peralta S
AD  - Endoscopia Digestiva - Policlinico P. Giaccone, Universita di Palermo, Palermo, 
      Italy
FAU - Nicita, R
AU  - Nicita R
AD  - Gastroenterologia - ASP 5, Reggio Calabria, Italy
FAU - Aragona, S E
AU  - Aragona SE
AD  - Center of Regenerative Medicine - Humanitas Mater Domini, Castellanza (VA), Italy
FAU - Ciprandi, G
AU  - Ciprandi G
AD  - Center of Regenerative Medicine - Humanitas Mater Domini, Castellanza (VA), Italy
CN  - EMERGE Study Group: A. Arrigoni, D. Artuso, M. Astegiano, C. Azzinnari, E. 
      Battaglia, C. Belcari, E. Bendia, P. Benedicenti, M. Bianchetti, G. Brandimarte, 
      I. Buoncompagni, M. Cabras, S. Camilleri, G. Capece, S. Caronna, C. Cassieri, F. 
      Castaldo, T. Catalano, C. Citarella, F. D'Amore, G. D'Alia, F. D'Arpa, A. 
      Dattola, N. De Bortoli, A. De Medici, S. Di Marzo, R. Di Mitri, A. Di Napoli, V. 
      D'Onofrio, L. Dughera, W. Elisei, G. Errico, L. Familiari, P. Familiari, R. 
      Frasca, A. Frunzio, M. Gatti, S. Genova, S. Grosso, R. Gullotta, D.R. 
      Iannuzziello, G. Indennitate, G. Leonardi, C. Luigiano, B. Macchiarella, T. 
      Maisto, M.G. Mancino, A. Mancino, G. Manes, R. Marin, G.R. Mastinu, A. Moi, L.M. 
      Montalbano, N. Monterosso, A. Morabito Loprete, L. Morlando, R. Nicita, C. 
      Ogliari, N. Paiano Primaldo, G. Paliani, A.P. Palieri, D. Pardocchi, A. Pati, G. 
      Pedretti, S. Peralta, A. Pisani, P. Plomaritis, A.C. Privitera, R. Pumpo, F. 
      Quatraro, D. Raimondo, G. Rivellini, L. Rizzo Giovanni, M. Romano, R. Salerno, E. 
      Savarino, G. Scarpulla, E. Sinagra, M. Soncini, G. Tammaro, C. Trovato, R. 
      Vassallo, M. Vinti, C.M.P. Virgilio.
AD  - Ospedale Policlinico San Martino, Genoa, Italy
LA  - eng
PT  - Letter
PL  - Italy
TA  - J Biol Regul Homeost Agents
JT  - Journal of biological regulators and homeostatic agents
JID - 8809253
RN  - 0 (Gastrointestinal Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - Gastroenterologists/statistics & numerical data
MH  - Gastroesophageal Reflux/*drug therapy
MH  - Gastrointestinal Agents/*therapeutic use
MH  - Humans
MH  - Italy
MH  - Male
MH  - Middle Aged
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - gastroesophageal reflux
OT  - gastroenterologist
OT  - diagnosis
OT  - treatment
EDAT- 2018/04/25 06:00
MHDA- 2019/05/07 06:00
CRDT- 2018/04/25 06:00
PHST- 2018/04/25 06:00 [entrez]
PHST- 2018/04/25 06:00 [pubmed]
PHST- 2019/05/07 06:00 [medline]
AID - 30 [pii]
PST - ppublish
SO  - J Biol Regul Homeost Agents. 2018 Jul-Aug;32(4):973-981.